Related Experiment Video
Updated: Mar 19, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
TRIM-ing Ligand Dependence in Castration-Resistant Prostate Cancer
Lalit R Patel1, Michelle C Barton1
1Department of Epigenetics and Molecular Carcinogenesis, Center for Cancer Epigenetics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX 77030, USA.
Abstract:
Prostate cancer is lethal when tumors evolve to activate androgen receptor signaling, which circumvents ligand-deprivation therapy. In this issue of Cancer Cell, Groner et al. show that histone reader and transcription co-regulator TRIM24 occupies a central role in this evolution, nominating inhibitors of TRIM24's bromodomain as a new therapeutic avenue.
Insights
Prostate tumors can become deadly by activating androgen receptor signaling, resisting treatment. Researchers found that TRIM24 drives this evolution, suggesting TRIM24 bromodomain inhibitors as a novel prostate cancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Prostate cancer progression is often linked to androgen receptor (AR) signaling.
- Tumor resistance to androgen-deprivation therapy (ADT) is a major clinical challenge.
- Understanding the molecular mechanisms driving treatment resistance is crucial for developing new therapies.
Purpose of the Study:
- To investigate the role of TRIM24 in the evolution of lethal prostate cancer.
- To identify potential therapeutic targets for overcoming resistance to ADT.
Main Methods:
- The study utilized molecular biology techniques to analyze TRIM24 function in prostate cancer models.
- Investigated the interaction of TRIM24 with AR signaling pathways.
- Evaluated the efficacy of TRIM24 bromodomain inhibitors.
Main Results:
- TRIM24 was identified as a key regulator in the activation of AR signaling during prostate cancer evolution.
- TRIM24 was found to be essential for tumor adaptation and resistance to ADT.
- Inhibition of TRIM24's bromodomain demonstrated therapeutic potential in preclinical models.
Conclusions:
- TRIM24 plays a critical role in the development of lethal, treatment-resistant prostate cancer.
- Targeting TRIM24, specifically its bromodomain, represents a promising new therapeutic strategy for advanced prostate cancer.
